{"denoms":[{"counts":[{"groupId":"BG000","value":"35"}],"units":"Participants"}],"groups":[{"description":"Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"BG000","title":"Treatment (DLI)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"28"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21","upperLimit":"74","value":"59.2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Italy"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}